Vishwas Seshadri Sells 25,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the sale, the chief executive officer now directly owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. This represents a 1.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Abeona Therapeutics Stock Performance

Shares of ABEO stock traded down $0.21 on Monday, hitting $4.76. The company had a trading volume of 867,546 shares, compared to its average volume of 410,115. The firm has a market cap of $231.02 million, a P/E ratio of -1.77 and a beta of 1.79. Abeona Therapeutics Inc has a twelve month low of $3.05 and a twelve month high of $8.45. The company has a 50-day moving average price of $5.41 and a 200-day moving average price of $5.81. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19. As a group, equities research analysts predict that Abeona Therapeutics Inc will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Twinbeech Capital LP acquired a new position in shares of Abeona Therapeutics in the fourth quarter worth about $58,000. Squarepoint Ops LLC purchased a new position in shares of Abeona Therapeutics in the 4th quarter valued at about $67,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics in the 3rd quarter worth about $84,000. Oxford Asset Management LLP acquired a new position in Abeona Therapeutics in the 4th quarter worth about $118,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Abeona Therapeutics during the third quarter worth approximately $151,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Analyst Upgrades and Downgrades

ABEO has been the subject of several research analyst reports. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 24th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, March 24th. Finally, Oppenheimer began coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.